329 related articles for article (PubMed ID: 23395587)
1. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
2. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
3. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
4. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Rafferty E; Duclos P; Yactayo S; Schuster M
Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
[TBL] [Abstract][Full Text] [Related]
5. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
6. [Surveillance system for adverse events following immunization against yellow fever in Burkina Faso in 2008. Good practice recommendations].
Yaméogo TM; Breugelmans JG; Kambou JL; Badolo O; Tiendrebéogo S; Traoré E; Avokey F; Yactayo S
Med Trop (Mars); 2009 Aug; 69(4):320-1. PubMed ID: 19725376
[TBL] [Abstract][Full Text] [Related]
7. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Curr Drug Saf; 2011 Jul; 6(3):145-54. PubMed ID: 22122389
[TBL] [Abstract][Full Text] [Related]
8. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
[TBL] [Abstract][Full Text] [Related]
9. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
van de Pol EM; Gisolf EH; Richter C
J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
[TBL] [Abstract][Full Text] [Related]
10. Enhanced safety surveillance of STAMARIL® yellow fever vaccine provided under the expanded access investigational new drug program in the USA.
Rojas A; Hachey W; Kaur G; Korejwo J; Muhammad R
J Travel Med; 2023 Nov; 30(7):. PubMed ID: 37000007
[TBL] [Abstract][Full Text] [Related]
11. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
[TBL] [Abstract][Full Text] [Related]
12. Safety of the yellow Fever vaccine: a retrospective study.
Nordin JD; Parker ED; Vazquez-Benitez G; Kharbanda EO; Naleway A; Marcy SM; Molitor B; Kuckler L; Baggs J
J Travel Med; 2013; 20(6):368-73. PubMed ID: 24118538
[TBL] [Abstract][Full Text] [Related]
13. Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.
Le Hir A; Durand GA; Boucraut J; Garnier A; Mura M; Diamantis S; Carles M; Durand C; Schweitzer C; Audouard C; Decroix V; Boyez R; Van Dendriessche A; Leclancher A; Kaphan E; Barbat du Closel L; Verdon R; du Cheyron D; Vabret A; Vergnon D; Grard G; Charrel R; de Lamballerie X; Eldin C
J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38123499
[TBL] [Abstract][Full Text] [Related]
14. A clinician's perspective on yellow fever vaccine-associated neurotropic disease.
Lecomte E; Laureys G; Verbeke F; Domingo Carrasco C; Van Esbroeck M; Huits R
J Travel Med; 2020 Nov; 27(7):. PubMed ID: 32965473
[TBL] [Abstract][Full Text] [Related]
15. Next generation live-attenuated yellow fever vaccine candidate: Safety and immuno-efficacy in small animal models.
Piras-Douce F; Raynal F; Raquin A; Girerd-Chambaz Y; Gautheron S; Sanchez MEN; Vangelisti M; Mantel N
Vaccine; 2021 Mar; 39(13):1846-1856. PubMed ID: 33685778
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
17. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination.
Silva ML; Espírito-Santo LR; Martins MA; Silveira-Lemos D; Peruhype-Magalhães V; Caminha RC; de Andrade Maranhão-Filho P; Auxiliadora-Martins M; de Menezes Martins R; Galler R; da Silva Freire M; Marcovistz R; Homma A; Teuwen DE; Elói-Santos SM; Andrade MC; Teixeira-Carvalho A; Martins-Filho OA
Clin Vaccine Immunol; 2010 Jan; 17(1):118-26. PubMed ID: 19906894
[TBL] [Abstract][Full Text] [Related]
18. Safety profile of fractional dosing of the 17DD Yellow Fever Vaccine among males and females: Experience of a community-based pharmacovigilance in Kinshasa, DR Congo.
Nzolo D; Engo Biongo A; Kuemmerle A; Lusakibanza M; Lula Y; Nsengi N; Nsibu Ndosimao C; Tona Lutete G; Van Geertruyden JP
Vaccine; 2018 Oct; 36(41):6170-6182. PubMed ID: 30190119
[TBL] [Abstract][Full Text] [Related]
19. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
Seligman SJ
Vaccine; 2014 Oct; 32(44):5769-75. PubMed ID: 25192973
[TBL] [Abstract][Full Text] [Related]
20. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Staples JE; Gershman M; Fischer M;
MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
